Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.
Identifieur interne : 000479 ( Main/Exploration ); précédent : 000478; suivant : 000480Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.
Auteurs : S. Yamaguchi ; M. Onji ; H. Kondoh ; H. Miyaoka ; Y. OhtaSource :
- Clinical and Experimental Immunology [ 0009-9104 ] ; 1988.
Abstract
Nine patients with chronic hepatitis type B were treated with recombinant interleukin 2 (rIL-2). Side effects were limited to low-grade fever and headache, which were transient and tolerable for the patients. Seven normal volunteers and nine patients with chronic active hepatitis were administered by one bolus of 500 units of rIL-2. Acute effects of rIL-2 administration on lymphoid cells included a rapid decrease in lymphocytes, especially in cytotoxic T cells and natural killer cells. These acute effects resolved within 24 hours. There was no difference in the changes of immunological parameters between normal volunteers and patients. The same effects were seen during 28 days of rIL-2 administration. The number of lymphocytes and CD4 positive cells was increased after rIL-2 administration for 28 days (P less than 0.01). Natural killer cell activity, especially that of CD16+ and Leu-7- cells was also increased (P less than 0.05). These effects may favour the elimination of virus-infected hepatocytes.
Url:
PubMed: 2975535
PubMed Central: 1541693
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000163
- to stream Pmc, to step Curation: 000055
- to stream Pmc, to step Checkpoint: 000205
- to stream Ncbi, to step Merge: 000238
- to stream Ncbi, to step Curation: 000238
- to stream Ncbi, to step Checkpoint: 000238
- to stream Main, to step Merge: 000480
- to stream Main, to step Curation: 000479
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.</title><author><name sortKey="Yamaguchi, S" sort="Yamaguchi, S" uniqKey="Yamaguchi S" first="S" last="Yamaguchi">S. Yamaguchi</name></author><author><name sortKey="Onji, M" sort="Onji, M" uniqKey="Onji M" first="M" last="Onji">M. Onji</name></author><author><name sortKey="Kondoh, H" sort="Kondoh, H" uniqKey="Kondoh H" first="H" last="Kondoh">H. Kondoh</name></author><author><name sortKey="Miyaoka, H" sort="Miyaoka, H" uniqKey="Miyaoka H" first="H" last="Miyaoka">H. Miyaoka</name></author><author><name sortKey="Ohta, Y" sort="Ohta, Y" uniqKey="Ohta Y" first="Y" last="Ohta">Y. Ohta</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">2975535</idno><idno type="pmc">1541693</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1541693</idno><idno type="RBID">PMC:1541693</idno><date when="1988">1988</date><idno type="wicri:Area/Pmc/Corpus">000163</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000163</idno><idno type="wicri:Area/Pmc/Curation">000055</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000055</idno><idno type="wicri:Area/Pmc/Checkpoint">000205</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000205</idno><idno type="wicri:Area/Ncbi/Merge">000238</idno><idno type="wicri:Area/Ncbi/Curation">000238</idno><idno type="wicri:Area/Ncbi/Checkpoint">000238</idno><idno type="wicri:doubleKey">0009-9104:1988:Yamaguchi S:immunologic:effects:on</idno><idno type="wicri:Area/Main/Merge">000480</idno><idno type="wicri:Area/Main/Curation">000479</idno><idno type="wicri:Area/Main/Exploration">000479</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.</title><author><name sortKey="Yamaguchi, S" sort="Yamaguchi, S" uniqKey="Yamaguchi S" first="S" last="Yamaguchi">S. Yamaguchi</name></author><author><name sortKey="Onji, M" sort="Onji, M" uniqKey="Onji M" first="M" last="Onji">M. Onji</name></author><author><name sortKey="Kondoh, H" sort="Kondoh, H" uniqKey="Kondoh H" first="H" last="Kondoh">H. Kondoh</name></author><author><name sortKey="Miyaoka, H" sort="Miyaoka, H" uniqKey="Miyaoka H" first="H" last="Miyaoka">H. Miyaoka</name></author><author><name sortKey="Ohta, Y" sort="Ohta, Y" uniqKey="Ohta Y" first="Y" last="Ohta">Y. Ohta</name></author></analytic><series><title level="j">Clinical and Experimental Immunology</title><idno type="ISSN">0009-9104</idno><idno type="eISSN">1365-2249</idno><imprint><date when="1988">1988</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Nine patients with chronic hepatitis type B were treated with recombinant interleukin 2 (rIL-2). Side effects were limited to low-grade fever and headache, which were transient and tolerable for the patients. Seven normal volunteers and nine patients with chronic active hepatitis were administered by one bolus of 500 units of rIL-2. Acute effects of rIL-2 administration on lymphoid cells included a rapid decrease in lymphocytes, especially in cytotoxic T cells and natural killer cells. These acute effects resolved within 24 hours. There was no difference in the changes of immunological parameters between normal volunteers and patients. The same effects were seen during 28 days of rIL-2 administration. The number of lymphocytes and CD4 positive cells was increased after rIL-2 administration for 28 days (P less than 0.01). Natural killer cell activity, especially that of CD16+ and Leu-7- cells was also increased (P less than 0.05). These effects may favour the elimination of virus-infected hepatocytes.</p></div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Kondoh, H" sort="Kondoh, H" uniqKey="Kondoh H" first="H" last="Kondoh">H. Kondoh</name><name sortKey="Miyaoka, H" sort="Miyaoka, H" uniqKey="Miyaoka H" first="H" last="Miyaoka">H. Miyaoka</name><name sortKey="Ohta, Y" sort="Ohta, Y" uniqKey="Ohta Y" first="Y" last="Ohta">Y. Ohta</name><name sortKey="Onji, M" sort="Onji, M" uniqKey="Onji M" first="M" last="Onji">M. Onji</name><name sortKey="Yamaguchi, S" sort="Yamaguchi, S" uniqKey="Yamaguchi S" first="S" last="Yamaguchi">S. Yamaguchi</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/DanceTherParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000479 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000479 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= DanceTherParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:1541693
|texte= Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:2975535" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a DanceTherParkinsonV1
| This area was generated with Dilib version V0.6.35. |  |